{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:07:27Z","timestamp":1779199647889,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22131002"],"award-info":[{"award-number":["22131002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22293014"],"award-info":[{"award-number":["22293014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2450076"],"award-info":[{"award-number":["T2450076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","award":["ITCPD\/17-9"],"award-info":[{"award-number":["ITCPD\/17-9"]}],"id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","award":["ITC-CNERC14SC01"],"award-info":[{"award-number":["ITC-CNERC14SC01"]}],"id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1501700"],"award-info":[{"award-number":["2021YFA1501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118864","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:10:26Z","timestamp":1776294626000},"page":"118864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of a novel HNF4\u03b1 agonist regulating abnormal metabolism"],"prefix":"10.1016","volume":"314","author":[{"given":"Tzumei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaochun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yameng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-9034","authenticated-orcid":false,"given":"Ning","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ejmech.2026.118864_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118864_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","article-title":"Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations","volume":"33","author":"Jeselsohn","year":"2018","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118864_bib4","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/onc.2016.382","article-title":"Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer","volume":"36","author":"Harrod","year":"2017","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118864_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118864_bib6","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118864_bib7","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"issue":"10215","key":"10.1016\/j.ejmech.2026.118864_bib8","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"9972","key":"10.1016\/j.ejmech.2026.118864_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118864_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pnpbp.2014.02.009","article-title":"PPAR-\u03b1 agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease","volume":"53","author":"Barbiero","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tips.2023.11.004","article-title":"PPAR agonists for the treatment of neuroinflammatory diseases","volume":"45","author":"Titus","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118864_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"issue":"10213","key":"10.1016\/j.ejmech.2026.118864_bib13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118864_bib14","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118864_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118864_bib16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2026.118864_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1226173","article-title":"HNF4\u03b1 isoforms: the fraternal twin master regulators of liver function","volume":"14","author":"Radi","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tem.2025.04.003","article-title":"Balancing metabolism and regeneration in liver diseases through HNF4\u03b1 targeting","volume":"37","author":"Van Dender","year":"2026","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118864_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115923","article-title":"Hepatocyte nuclear factor 4 a (HNF4\u03b1): a perspective in cancer","volume":"169","author":"Qu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118864_bib20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.yexcr.2009.01.004","article-title":"Novel P2 promoter-derived HNF4\u03b1 isoforms with different N-terminus generated by alternate exon insertion","volume":"315","author":"Huang","year":"2009","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118864_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.coph.2010.08.010","article-title":"HNF4\u03b1\u2014role in drug metabolism and potential drug target?","volume":"10","author":"Hwang-Verslues","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118864_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1872-034X.2008.00367.x","article-title":"Transcription factor HNF and hepatocyte differentiation","volume":"38","author":"Nagaki","year":"2008","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118864_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1101\/gad.14.4.464","article-title":"Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha","volume":"14","author":"Li","year":"2000","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118864_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng1175","article-title":"Hepatocyte nuclear factor 4\u03b1 controls the development of a hepatic epithelium and liver morphogenesis","volume":"34","author":"Parviz","year":"2003","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2133\/dmpk.23.2","article-title":"Regulation of hepatocyte nuclear factor 4\u03b1-mediated transcription","volume":"23","author":"Gonzalez","year":"2008","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib26","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/ncomms8466","article-title":"A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism","volume":"6","author":"Xu","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118864_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.32326","article-title":"Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans","volume":"76","author":"Gunewardena","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.118864_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155371","article-title":"Impaired hepatic glucose metabolism and liver-\u03b1-cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4\u03b1 (Hnf4a) gene","volume":"139","author":"Thymiakou","year":"2023","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118864_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/ATVBAHA.110.217828","article-title":"Hepatic hepatocyte nuclear factor 4\u03b1 is essential for maintaining triglyceride and cholesterol homeostasis","volume":"31","author":"Yin","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118864_bib30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/MCB.21.4.1393-1403.2001","article-title":"Hepatocyte nuclear factor 4\u03b1 (nuclear receptor 2a1) is essential for maintenance of hepatic gene expression and lipid homeostasis","volume":"21","author":"Hayhurst","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118864_bib31","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/hep.31604","article-title":"Hepatocyte nuclear factor 4\u03b1 prevents the steatosis\u2010to\u2010nash progression by regulating p53 and bile acid signaling (in mice)","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118864_bib32","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/cb4000986","article-title":"Identification of alverine and benfluorex as HNF4\u03b1 activators","volume":"8","author":"Lee","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118864_bib33","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1016\/j.bmc.2009.07.079","article-title":"Identification of small molecule regulators of the nuclear receptor HNF4\u03b1 based on naphthofuran scaffolds","volume":"17","author":"Le Gu\u00e9vel","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118864_bib34","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.3390\/ijms21217895","article-title":"Chemical starting matter for HNF4\u03b1 Ligand discovery and chemogenomics","volume":"21","author":"Meijer","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118864_bib35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41419-021-03862-x","article-title":"Liver fat storage is controlled by HNF4\u03b1 through induction of lipophagy and is reversed by a potent HNF4\u03b1 agonist","volume":"12","author":"Lee","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-022-04521-5","article-title":"Long-term oral administration of an HNF4\u03b1 agonist prevents weight gain and hepatic steatosis by promoting increased mitochondrial mass and function","volume":"13","author":"Veeriah","year":"2022","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118864_bib37","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.1021\/acs.jmedchem.5c00595","article-title":"A first-in-class hepatocyte nuclear factor 4 agonist","volume":"68","author":"Schallmayer","year":"2025","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118864_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s43588-024-00737-x","article-title":"Structure-based drug design with equivariant diffusion models","volume":"4","author":"Schneuing","year":"2024","journal-title":"Nat. Comput. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib39","article-title":"HNF4A ameliorates acute liver failure by inhibiting NCOA4-mediated ferritinophagy","volume":"15","author":"Yu","year":"2025","journal-title":"Sci Rep."},{"key":"10.1016\/j.ejmech.2026.118864_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101211","article-title":"Ferroptosis is governed by differential regulation of transcription in liver cancer","volume":"24","author":"Zhang","year":"2019","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118864_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-05868-z","article-title":"HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118864_bib42","article-title":"HNF4\u03b1 regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer","volume":"11","author":"Xu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118864_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.toxrep.2014.02.003","article-title":"Hypolipidemic action of chrysin on Triton WR-1339-induced hyperlipidemia in female C57BL\/6 mice","volume":"1","author":"Zarzecki","year":"2014","journal-title":"Toxicol. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118864_bib44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.etap.2012.01.004","article-title":"The impact of Triton WR-1339 induced hyperlipidemia on the effects of benzo(a)pyrene or guaiacol on \u03b1- and \u03b3-tocopherol pools and selected markers of pro-\/antioxidative balance in rat plasma and erythrocytes","volume":"33","author":"Gawlik","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118864_bib45","series-title":"GROMACS 2022.5 Source Code","author":"Lindahl","year":"2022"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118864_bib46","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118864_bib47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.118864_bib48","series-title":"Gaussian 16 Rev. C.01","author":"Frisch","year":"2019"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118864_bib49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.118864_bib50","series-title":"2022, Sobtop 1.0(dev3.1)","author":"Lu","year":"2022"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118864_bib51","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118864_bib52","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118864_bib53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/cn500193f","article-title":"Syntheses and evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-Aza-2-oxindole scaffold as trk PET imaging agents","volume":"6","author":"Bernard-Gauthier","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118864_bib54","series-title":"NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES. WO2004DK00875, 2004\/12\/16\/Application Date","author":"Elysa","year":"2004"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118864_bib55","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11030-020-10088-0","article-title":"Structure\u2013activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety","volume":"25","author":"Yang","year":"2021","journal-title":"Mol. Divers."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:32Z","timestamp":1779196292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S0223523426003090"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118864","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a novel HNF4\u03b1 agonist regulating abnormal metabolism","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118864"}}